NCT07584447Not yet recruiting
Clinical Utility of Preoperative Thyroid GuidePx® Testing
Source: ClinicalTrials.gov · Last updated 1 Jun 2026
Brief summary (registry, in English)
The purpose of this study is to learn whether having Thyroid GuidePx® test results available before treatment may help patients with papillary thyroid cancer and doctors make better-informed treatment decisions.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 85 (estimated)
- First submitted
- 13 Jan 2026
- Start date
- Apr 2026
- Primary completion date
- Apr 2028
- Lead sponsor
- University of Calgary
- Diseases
- Thyroid cancer
- NCT number
- NCT07584447
What you commit to
- Study type: Observational
- Planned participants: 85
- From Apr 2026 to the primary completion date, Apr 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior thyroid operation
Other illness
- Distant metastatic disease
- Personal history of thyroid cancer
- History of whole-body radiation exposure or radiation to the head and neck region
Who the study is looking for
- Patients aged 18 years or older at the time of enrollment
- English-speaking
- Bethesda V or VI cytology following FNA of a thyroid nodule (papillary thyroid cancer)
- Bethesda III or IV with ThyroSpec positive for BRAFV600E, TERT, rearrangements in BRAF, RET, NTRK1, NTRK3, RAS + TERT, RAS + EIF1AX, AKT1, PI3CA, CTNNB1, EGFR, rearrangements in ALK
- Tumor 1- 4cm in size
- No lymph node involvement on ultrasound
- No gross extrathyroidal extension on ultrasound
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.